Agilent Technologies (A) FY2025 10-K Annual Report

Filed: Dec 22, 2025
Health Care
Laboratory Analytical InstrumentsSEC EDGAR

Agilent Technologies (A) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Dec 22, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Agilent Technologies FY2025 10-K Analysis

Business Overview

  • Core business model: Provider of scientific instruments and analytical solutions for laboratories and research
  • No new products, services, or business segments introduced or emphasized in this year's filing
  • Continued focus on equity compensation plans, including 2018 Stock Plan with 38.8 million shares available for future issuance
  • Notable metric: 2,954,318 securities outstanding under equity compensation plans with weighted-average exercise price $134
  • Most unusual detail: Annual increase mechanism in Employee Stock Purchase Plan allows up to 1% of outstanding shares for future issuance

Management Discussion & Analysis

  • Revenue and profitability figures not disclosed in provided MD&A text
  • No segment performance data provided in excerpt
  • No cash flow, buybacks, dividends, or capex details mentioned
  • Forward-looking statements highlight growth opportunities, investments, market demand, and macroeconomic risks without specific guidance or figures

Risk Factors

  • Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025
  • Geopolitical risk from U.S. tariff changes in H2 2025 increasing cost of revenue; mitigation expected in fiscal 2026 through supply chain and pricing actions
  • Operational risk in inventory valuation: potential write-downs if actual market conditions worsen beyond management's estimates on excess and obsolete inventory
  • Competitive risk from capital spending declines in pharmaceutical market affecting Life Sciences and Diagnostics segment revenue growth, down 11% in 2024 vs 2023
  • Financial risk from goodwill and intangible asset impairment assessment, relying on significant estimates including revenue growth and discount rates, with no impairment recognized in 2025

Agilent Technologies FY2025 Key Financial Metrics
XBRL

Revenue

$6.9B

+6.7% YoY

Net Income

$1.3B

+1.1% YoY

Operating Margin

21.3%

-157bp YoY

Net Margin

18.8%

-105bp YoY

ROE

19.3%

-253bp YoY

Total Assets

$12.7B

+7.4% YoY

EPS (Diluted)

$4.57

+3.2% YoY

Operating Cash Flow

$1.6B

-11.0% YoY

Source: XBRL data from Agilent Technologies FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Agilent Technologies

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.